NCT07014826

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of HRS-5965 Capsule in Primary IgA Nephropathy

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 378 (estimated)
• Sponsor: Chengdu Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.

Conditions

• Primary IgA Nephropathy

Interventions

Type	Name	Description
DRUG	HRS-5965	HRS-5965
DRUG	Placebo	Placebo

Timeline

• Start date: 2025-06-04
• Primary completion: 2027-10-01
• Completion: 2028-12-01
• First posted: 2025-06-11
• Last updated: 2025-08-05

Locations

1 site across 1 country: China